Answers are grounded in this paper and cite their sources.
Background Mucosa-associated invariant T (MAIT) cells are innate-like T lymphocytes that bridge innate and adaptive immunity. While their dysfunction is implicated in various cancers, their role in multiple myeloma (MM), particularly the dominant CD8 + MAIT subset, remains poorly defined. Objective To investigate the frequency, phenotype, function, and clinical relevance of MAIT cells, with a focus on CD8 + MAIT cells, in MM patients. Methods We analyzed peripheral blood (PB) and bone marrow (BM) samples from 120 MM patients (77 newly diagnosed, 22 in remission, 21 relapsed) and 30 healthy controls (HCs) using multi-color flow cytometry to assess MAIT cell frequency, subset distribution, activation (programmed cell death protein 1 (PD-1) expression), and effector function (cytokine production and cytotoxic molecule expression). Clinical parameters and survival outcomes were correlated with MAIT cell levels. Results MM patients demonstrated a significant reduction in total MAIT cell frequency, driven primarily by a loss of CD8 + MAIT cells. These cells exhibited a functional dysfunction phenotype marked by PD-1 upregulation. Functionally, they showed impaired production of interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) upon activation but elevated constitutive expression of granzyme B and perforin. Lower MAIT cell levels correlated with adverse clinical features ( e.g. , elevated β2-microglobulin, lactate dehydrogenase (LDH), BM plasma cell infiltration) and advanced disease stage. Multivariate analysis identified baseline MAIT cell frequency as independently associated with overall survival (hazard ratio (HR) = 5.140, p = 0.048). Patients achieving complete remission showed a partial recovery of MAIT cell counts. Conclusion The numerical and functional impairment of MAIT cells, especially the CD8 + subset, is associated with disease progression and immune dysregulation in MM. Our findings highlight MAIT cells as potential prognostic biomarkers and candidates for immunotherapeutic strategies in MM.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: